A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.

The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populati...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowsett, M., Harris, A. L., Stuart-Harris, R., Hill, M., Cantwell, B. M., Smith, I. E., Jeffcoate, S. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1985
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977250/
https://www.ncbi.nlm.nih.gov/pubmed/2933050
_version_ 1782135221635776512
author Dowsett, M.
Harris, A. L.
Stuart-Harris, R.
Hill, M.
Cantwell, B. M.
Smith, I. E.
Jeffcoate, S. L.
author_facet Dowsett, M.
Harris, A. L.
Stuart-Harris, R.
Hill, M.
Cantwell, B. M.
Smith, I. E.
Jeffcoate, S. L.
author_sort Dowsett, M.
collection PubMed
description The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populations, but the mean age and weight of the groups were similar and there were no significant differences between the pretreatment serum levels of the hormones investigated. Serum oestrone and oestradiol levels were suppressed by both treatments, but there was a significantly greater suppression by AG + HC. This greater suppression is probably due to the observed increase in serum androstenedione (i.e. precursor) levels with AG alone, whilst with AG + HC these levels were found to be reduced. In terms of suppression of serum oestrogen levels it is of benefit to combine low dose AG with HC.
format Text
id pubmed-1977250
institution National Center for Biotechnology Information
language English
publishDate 1985
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19772502009-09-10 A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Dowsett, M. Harris, A. L. Stuart-Harris, R. Hill, M. Cantwell, B. M. Smith, I. E. Jeffcoate, S. L. Br J Cancer Research Article The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populations, but the mean age and weight of the groups were similar and there were no significant differences between the pretreatment serum levels of the hormones investigated. Serum oestrone and oestradiol levels were suppressed by both treatments, but there was a significantly greater suppression by AG + HC. This greater suppression is probably due to the observed increase in serum androstenedione (i.e. precursor) levels with AG alone, whilst with AG + HC these levels were found to be reduced. In terms of suppression of serum oestrogen levels it is of benefit to combine low dose AG with HC. Nature Publishing Group 1985-10 /pmc/articles/PMC1977250/ /pubmed/2933050 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Dowsett, M.
Harris, A. L.
Stuart-Harris, R.
Hill, M.
Cantwell, B. M.
Smith, I. E.
Jeffcoate, S. L.
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
title A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
title_full A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
title_fullStr A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
title_full_unstemmed A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
title_short A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
title_sort comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977250/
https://www.ncbi.nlm.nih.gov/pubmed/2933050
work_keys_str_mv AT dowsettm acomparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT harrisal acomparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT stuartharrisr acomparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT hillm acomparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT cantwellbm acomparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT smithie acomparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT jeffcoatesl acomparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT dowsettm comparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT harrisal comparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT stuartharrisr comparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT hillm comparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT cantwellbm comparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT smithie comparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients
AT jeffcoatesl comparisonoftheendocrineeffectsoflowdoseaminoglutethimidewithandwithouthydrocortisoneinpostmenopausalbreastcancerpatients

Ejemplares similares